Selective activation of E-type prostanoid3-receptors reduces myocardial infarct size: A novel insight into the cardioprotective effects of prostaglandins

Pharmacology and Therapeutics

Volumn 87, Issue 1, 2000, Pages 61-67

  Thiemermann, Christoph ^a   Zacharowski, Kai ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cardioprotection; EP3 receptor agonists; M and B 28767; ONO AE 248; Potassium channels; Protein kinase C

Indexed keywords

11 DEOXY 16 PHENOXY 17,18,19,20 TETRANORPROSTAGLANDIN E1; ADENYLATE CYCLASE; ICOSANOID; POTASSIUM CHANNEL; PROSTAGLANDIN; PROSTANOID; PROSTANOID RECEPTOR; PROTEIN KINASE C;

ARTERY OCCLUSION; CAT; CELL PROTECTION; CORONARY ARTERY BLOOD FLOW; HEART AFTERLOAD; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TISSUE INJURY;

ANIMALS; HUMANS; MYOCARDIAL INFARCTION; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN E;

EID: 0033866177     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00069-3     Document Type: Review

References (74)

1. Baller D., Bretschneider H.J., Hellige G. A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res Cardiol. 76:1981;163-181.
2. Barst S., Mullane K. The release of a leukotriene D4-like substance following myocardial infarction in rabbits. Eur J Pharmacol. 114:1985;383-387.
3. Baxter G.F., Yellon D.M. ATP-sensitive K+ channels mediate the delayed cardioprotective effect of adenosine A1 receptor activation. J Mol Cell Cardiol. 31:1999;981-989.
4. Brezinski M.E., Yanagisawa A., Darius H., Lefer A.M. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats. Am Heart J. 110:1985;1161-1167.
5. Burke S.E., Lefer A.M., Smith G.M., Smith J.B. Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor. Br J Clin Pharmacol. 15:1983;97S-101S.
6. Chien K.R., Han A., Sen A., Buja L.M., Willerson J.T. Accumulation of unesterified arachidonic acid in ischemic canine myocardium. Relationship to a phosphatidylcholine deacylation-reacylation cycle and the depletion of membrane phospholipids. Circ Res. 54:1984;313-322.
7. Coker S.J., Parratt J.R. Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds. Br J Clin Pharmacol. 15:1983;87S-95S.
8. Coker S.J., Parratt J.R., Ledingham I.M., Zeitlin I.J. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature. 291:1981;323-324.
9. Coleman, R. A., Kennedy, I., Humphrey, P. P. A., Brunce, K., & Lumley, P. (1990). In C. Hansch, P. G. Samnes, J. B. Taylor, & J. C. Emmet (Eds.) Comprehensive Medicinal Chemistry (pp. 643-651). Oxford: Pergamon Press.
10. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors. properties, distribution, and structure of the receptors and their subtypes Pharmacol Rev. 46:1994;205-229.
11. Corey E.J., Niwa H., Falck J.R., Mioskowski C., Arai Y., Marfat A. Recent studies on the chemical synthesis of eicosanoids. Adv Prostaglandin Thromboxane Res. 6:1980;19-25.
12. de Deckere E.A., Nugteren D.H., Ten Hoor F. Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature. 268:1977;160-163.
13. Dix R.K., Kelliher G.J., Jurkiewicz N., Lawrence T. The influence of prostacyclin on coronary occlusion induced arrhythmia in cats. Prostaglandins Med. 3:1979;173-184.
14. Downey J.M., Cohen M.V. Signal transduction in ischemic preconditioning. Z Kardiol. 84:1995;77-86.
15. Downey J.M., Liu G.S., Thornton J.D. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res. 27:1993;3-8.
16. Garlid K.D., Paucek P., Yarov-Yarovoy V., Murray H.N., Darbenzio R.B., D'Alonzo A.J., Lodge N.J., Smith M.A., Grover G.J. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res. 81:1997;1072-1082.
17. Goetzl E.J., Woods J.M., Gorman R.R. Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. J Clin Invest. 59:1977;179-183.
18. Goto M., Liu Y., Yang X.M., Ardell J.L., Cohen M.V., Downey J.M. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 77:1995;611-621.
19. Gross G.J., Fryer R.M. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res. 84:1999;973-979.
20. Hamberg M., Svensson J., Samuelsson B. Thromboxanes. a new group of biologically active compounds derived from prostaglandin endoperoxides Proc Natl Acad Sci USA. 72:1975;2994-2998.
21. Hide E.J., Thiemermann C. Sulprostone-induced reduction of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol. 118:1996;1409-1414.
22. Hide E.J., Ney P., Piper J., Thiemermann C., Vane J.R. Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol. 116:1995;2435-2440.
23. Hohlfeld T. Regulation of prostaglandin receptors in myocardial ischemia. Agents Actions Suppl. 45:1995;33-37.
24. Hohlfeld T., Zucker T.P., Meyer J., Schror K. Expression, function, and regulation of E-type prostaglandin receptors (EP3) in the nonischemic and ischemic pig heart. Circ Res. 81:1997;765-773.
25. Hohlfeld T., Meyer J., Schror K. Myocardial EP3 receptors are externalized ischemic porcine hearts and mediate reduction of ischemic myocardial injury. Naunyn Schmiedebergs Arch Pharmacol. 357:1998;R103.
26. Hutton I., Parratt J.R., Lawrie T.D. Cardiovascular effects of prostaglandin E 1 in experimental myocardial infarction. Cardiovasc Res. 7:1973;149-155.
27. Jodalen H., Stangeland L., Grong K., Vik-Mo H., Lekven J. Lipid accumulation in the myocardium during acute regional ischaemia in cats. J Mol Cell Cardiol. 17:1985;973-980.
28. Jouve R., Puddu P.E. Prostacyclin and protection of the ischemic myocardium. Cardiologia. 33:1988;339-341.
29. Jugdutt B.I., Hutchins G.M., Bulkley B.H., Becker L.C. Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res. 49:1981;685-700.
30. Kaye A.D., Nossaman B.D., Ibrahim I.N., Feng C.J., Kadowitz P.J. Influence of protein kinase C inhibitors on vasoconstrictor responses in the pulmonary vascular bed of cat and rat. Am J Physiol. 268:1995;L532-L538.
31. Kloner R.A., Ganote C.E., Jennings R.B. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 54:1974;1496-1508.
32. Kozak W., Klir J.J., Conn C.A., Kluger M.J. Attenuation of lipopolysaccharide fever in rats by protein kinase C inhibitors. Am J Physiol. 273:1997;R873-R879.
33. Lefer A.M., Ogletree M.L., Smith J.B., Silver M.J., Nicolaou K.C., Barnette W.E., Gasic G.P. Prostacyclin. a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia Science. 200:1978;52-54.
34. Leinberger H., Suehiro G.T., McNamara J.J. Myocardial platelet trapping after coronary ligation in primates (Papio anubis). J Surg Res. 27:1979;36-40.
35. Liang B.T., Gross G.J. Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. Circ Res. 84:1999;1396-1400.
36. Liu Y., Ytrehus K., Downey J.M. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol. 26:1994;661-668.
37. Lucchesi B.R., Mullane K.M. Leukocytes and ischemia-induced myocardial injury. Annu Rev Pharmacol Toxicol. 26:1986;201-224.
38. McCluskey E.R., Murphree S., Saffitz J.E., Morrison A.R., Needleman P. Temporal changes in 12-HETE formation in two models of canine myocardial infarction. Prostaglandins. 29:1985;387-403.
39. Meerson F.Z., Kagan V.E., Kozlov Y.P., Belkina L.M., Arkhipenko Y.V. The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. Basic Res Cardiol. 77:1982;465-485.
40. Mentzer R.M. Jr., Bunger R., Lasley R.D. Adenosine enhanced preservation of myocardial function and energetics. Possible involvement of the adenosine A1 receptor system. Cardiovasc Res. 27:1993;28-35.
41. Moncada S., Vane J.R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 30:1978;293-331.
42. Noda K., Sasaguri M., Ideishi M., Ikeda M., Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res. 27:1993;334-340.
43. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 305:1983;147-148.
44. Ogletree M.L., Lefer A.M. Prostaglandin-induced preservation of the ischemic myocardium. Circ Res. 42:1978;218-224.
45. Parratt J.R., Coker S.J. Arachidonic acid cascade and the generation of ischemia- and reperfusion-induced ventricular arrhythmias. J Cardiovasc Pharmacol. 7:1985;S65-S70.
46. Parratt J.R., Kane K.A. KATP channels in ischaemic preconditioning. Cardiovasc Res. 28:1994;783-787.
47. Parratt J.R., Coker S.J., Wainwright C.L. Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. J Mol Cell Cardiol. 19:1987;55-66.
48. Prinzen F.W., Van der Vusse G.J., Arts T., Roemen T.H., Coumans W.A., Reneman R.S. Accumulation of nonesterified fatty acids in ischemic canine myocardium. Am J Physiol. 247:1984;H264-H272.
49. Riemersma R.A., Talbot R.C., Ungar A., Mjos O.D., Oliver M.F. Effects of prostaglandin-E1 on ST segment elevation and regional myocardial blood flow during experimental myocardial ischaemia in dogs. Eur J Clin Invest. 7:1977;515-521.
50. Schmitz J.M., Apprill P.G., Buja L.M., Willerson J.T., Campbell W.B. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischemia. Circ Res. 57:1985;223-231.
51. Schror K. Eicosanoids and myocardial ischaemia. Basic Res Cardiol. 82:1987;235-243.
52. Schror K., Thiemermann C. Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177). Br J Pharmacol. 87:1986;631-637.
53. Schror K., Thiemermann C. Eicosanoids in myocardial ischemia. Biomed Biochim Acta. 48:1989;729-734.
54. Schror K., Smith E.F. III, Bickerton M., Smith J.B., Nicolaou K.C., Magolda R., Lefer A.M. Preservation of ischemic myocardium by pinane thromboxane A2. Am J Physiol. 238:1980;H87-H92.
55. Schror K., Thiemermann C., Ney P. Protection of the ischemic myocardium from reperfusion injury by prostaglandin E1 inhibition of ischemia-induced neutrophil activation. Naunyn Schmiedebergs Arch Pharmacol. 338:1988;268-274.
56. Serneri G.G., Masotti G., Poggesi L., Galanti G., Morettini A., Scarti L. Reduced prostacyclin production in patients with different manifestations of ischemic heart disease. Am J Cardiol. 49:1982;1146-1151.
57. Shaikh N.A., Downar E. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ Res. 49:1981;316-325.
58. Smith E.F. 3rd, Lefer A.M., Smith J.B. Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Can J Physiol Pharmacol. 58:1980;294-300.
59. Speechly-Dick M.E., Mocanu M.M., Yellon D.M. Protein kinase C. Its role in ischemic preconditioning in the rat. Circ Res. 75:1994;586-590.
60. Szekeres L., Pataricza J., Szilvassy Z., Udvary E., Vegh A. Cardioprotection. endogenous protective mechanisms promoted by prostacyclin Basic Res Cardiol. 86:1991;215-221.
61. Terashita Z.I., Fukui H., Nishikawa K., Hirata M., Kikuchi S. Coronary vasospastic action of thromboxane A2 in isolated, working guinea pig hearts. Eur J Pharmacol. 53:1978;49-56.
62. Thiemermann C., Ney P., Schror K. The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis. Eur J Pharmacol. 155:1988;57-67.
63. Trachte G.J., Lefer A.M., Aharony D., Smith J.B. Potent constriction of cat coronary arteries by hydroperoxides of arachidonic acid and its blockade by anti-inflammatory agents. Prostaglandins. 18:1979;909-914.
64. Uchida Y., Hanai T., Hasegawa K., Kawamura K., Oshima T. Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Adv Prostaglandin Thromboxane Leukot Res. 11:1983;377-383.
65. van Bilsen M., Engels W., van der Vusse G.J., Reneman R.S. Significance of myocardial eicosanoid production. Mol Cell Biochem. 88:1989;113-121.
66. van der Vusse G.J., Reneman R.S. The myocardial non-esterified fatty acid controversy. J Mol Cell Cardiol. 16:1984;677-682.
67. Vik-Mo H. Platelet accumulation in the myocardium during acute nonthrombotic coronary artery occlusion in dogs. Scand J Haematol. 21:1978;225-232.
68. Wang Y.G., Lipsius S.L. Acetylcholine activates a glibenclamide-sensitive K+ current in cat atrial myocytes. Am J Physiol. 268:1995;H1322-H1334.
69. Yao Z., Gross G.J. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol. 264:1993;H2221-H2225.
70. Yoshida K., Kawamura S., Mizukami Y., Kitakaze M. Implication of protein kinase C-alpha, delta, and epsilon isoforms in ischemic preconditioning in perfused rat hearts. J Biochem (Tokyo). 122:1997;506-511.
71. Ytrehus K., Liu Y., Downey J.M. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 266:1994;H1145-H1152.
72. Zacharowski K., Olbrich A., Otto M., Hafner G., Thiemermann C. Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 126:1999;849-858. a.
73. Zacharowski K., Olbrich A., Piper J., Hafner G., Kondo K., Thiemermann C. Selective activation of the prostanoid EP(3) receptor reduces myocardial infarct size in rodents. Arterioscler Thromb Vasc Biol. 19:1999;2141-2147. b.
74. Zacharowski K., Olbrich A., Thiemermann C. Reduction of myocardial injury by the EP3 receptor agonist TEI-3356. Role of protein kinase C and of K(ATP)-channels. Eur J Pharmacol. 367:1999;33-39. c.